KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. The presentation will be followed by a question and answer session that will begin at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit .

Every Second Counts!™

Kiniksa Investor and Media Contact

Mark Ragosa

(781) 430-8289

 

EN
10/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care...

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical compan...

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch